Canntab Therapeutics Limited
CTABF · OTC
5/31/2022 | 5/31/2021 | 5/31/2020 | 5/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.22 | 9.27 | 0.65 |
| FCF Yield | -30.75% | -9.24% | -9.40% | -14.24% |
| EV / EBITDA | -4.30 | -11.06 | -12.46 | -7.52 |
| Quality | ||||
| ROIC | -230.41% | -71.25% | -60.90% | -105.95% |
| Gross Margin | -320.09% | 0.00% | 100.00% | 59.84% |
| Cash Conversion Ratio | 0.77 | 0.64 | 0.73 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | 30.06% | -100.00% | 71.00% | – |
| Free Cash Flow Growth | 8.16% | -13.90% | -5.81% | -80.59% |
| Safety | ||||
| Net Debt / EBITDA | -0.46 | -0.02 | 0.60 | 0.17 |
| Interest Coverage | -7.35 | -18.65 | -98.41 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.52 | 0.15 | 0.00 | 0.00 |
| Cash Conversion Cycle | 358.18 | 977.72 | 104.59 | 170.31 |